Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...

The FDA has approved delgocitinib cream as a topical treatment for moderate-to-severe chronic hand eczema (CHE) in adults, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

Studies leading up to the FDA approval found that people with hand eczema who used the cream were more likely to improve than ...

Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA. The agency approved ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...